Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases.

Gulati, N; Dua, K; Dureja, H

Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases.

Gulati, N Dua, K

Dureja, H

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: International journal of biological macromolecules, 2021
Issue Date:: 2021-06-08

Closed Access

	Filename	Description	Size
	1-s2.0-S0141813021012368-main.pdf	Published version	1.76 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gulati, N
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Dureja, H
dc.date.accessioned	2021-06-18T11:01:42Z
dc.date.available	2021-06-05
dc.date.available	2021-06-18T11:01:42Z
dc.date.issued	2021-06-08
dc.identifier.citation	International journal of biological macromolecules, 2021
dc.identifier.issn	0141-8130
dc.identifier.issn	1879-0003
dc.identifier.uri	http://hdl.handle.net/10453/149638
dc.description.abstract	Chitosan-loaded nanomedicines provide a greater opportunity for the treatment of respiratory diseases. Natural biopolymer chitosan and its derivatives have a large number of proven pharmacological actions like antioxidant, wound healing, immuno-stimulant, hypocholesterolemic, antimicrobial, obesity treatment, anti-inflammatory, anticancer, bone tissue engineering, antifungal, regenerative medicine, anti-diabetic and mucosal adjuvant, etc. which attracted its use in the pharmaceutical industry. As compared to other polysaccharides, chitosan has excellent mucoadhesive characteristics, less viscous, easily modified into the chemical and biological molecule and gel-forming property due to which the drugs retain in the respiratory tract for a longer period of time providing enhanced therapeutic action of the drug. Chitosan-based nanomedicines would have the greatest effect when used to transport poor water soluble drugs, macromolecules like proteins, and peptides through the lungs. In this review, we highlight and discuss the role of chitosan and its nanomedicines in the treatment of chronic respiratory diseases such as pneumonia, asthma, COPD, lung cancer, tuberculosis, and COVID-19.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	International journal of biological macromolecules
dc.relation.isbasedon	10.1016/j.ijbiomac.2021.06.035
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology
dc.subject.classification	Polymers
dc.title	Role of chitosan based nanomedicines in the treatment of chronic respiratory diseases.
dc.type	Journal Article
utslib.location.activity	Netherlands
utslib.for	0601 Biochemistry and Cell Biology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2021-06-18T11:01:40Z
pubs.publication-status	Published

Abstract:

Chitosan-loaded nanomedicines provide a greater opportunity for the treatment of respiratory diseases. Natural biopolymer chitosan and its derivatives have a large number of proven pharmacological actions like antioxidant, wound healing, immuno-stimulant, hypocholesterolemic, antimicrobial, obesity treatment, anti-inflammatory, anticancer, bone tissue engineering, antifungal, regenerative medicine, anti-diabetic and mucosal adjuvant, etc. which attracted its use in the pharmaceutical industry. As compared to other polysaccharides, chitosan has excellent mucoadhesive characteristics, less viscous, easily modified into the chemical and biological molecule and gel-forming property due to which the drugs retain in the respiratory tract for a longer period of time providing enhanced therapeutic action of the drug. Chitosan-based nanomedicines would have the greatest effect when used to transport poor water soluble drugs, macromolecules like proteins, and peptides through the lungs. In this review, we highlight and discuss the role of chitosan and its nanomedicines in the treatment of chronic respiratory diseases such as pneumonia, asthma, COPD, lung cancer, tuberculosis, and COVID-19.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/149638